Tirzepatide 10mg - New Generation Fat Loss

Tirzepatide is a once-weekly injectable medication developed by Eli Lilly. It acts as a dual GIP and GLP-1 receptor agonist (often referred to as a “twincretin”).

For Weight Loss & Obesity:

• Potent appetite suppression and reduced cravings

• Clinical trials have shown average weight loss of 15–22% depending on dose and duration

• Improves key cardiometabolic markers including blood pressure, triglycerides, cholesterol, and waist circumference

Other Potential Benefits (under investigation):

• Cardiovascular risk reduction

• Possible improvements in fatty liver disease (NAFLD/NASH)